Literature DB >> 10870113

Age-related expression of the cellular prion protein in human peripheral blood leukocytes.

G Politopoulou1, J D Seebach, M Schmugge, H P Schwarz, A Aguzzi.   

Abstract

BACKGROUND AND
OBJECTIVE: Creutzfeldt-Jakob disease typically affects older patients, yet victims of new-variant Creutzfeldt-Jakob disease (nvCJD) are unusually young. Because the cellular prion protein PrP(C) is required for disease development, we investigated age-dependent variability in cell surface PrP(C) expression on various subclasses of human peripheral blood leukocytes (PBL) as a possible susceptibility factor. DESIGN AND METHODS: Three age groups of healthy individuals (mean ages: 6, 33 and 68) were studied by two-color FACS analysis of PBL with fluorescent monoclonal antibodies to PrP(C) and to the lineage markers CD3, CD19, CD4, and CD8. For each subclass marker, surface PrP(C) levels were expressed as mean fluorescence intensity ratios (MFIR) by dividing the geometric mean of the fluorescence of each test antibody by the geometric mean of its isotype-matched control antibody. PrP(C) expression levels in each age and lineage group were compared using appropriate non-parametric tests.
RESULTS: We found significant age-related differences in PrP(C) expression on lymphocytes (p=0. 0004). The elderly expressed significantly higher levels than children (p=0.0006) and adults (p=0.0009). PrP(C) expression was also significantly higher in CD3(+) compared to CD19(+ )(p=0.0004) and in CD8(+) compared to CD4(+ )lymphocytes (p=0.0044). INTERPRETATION AND
CONCLUSIONS: If PrP(C) expression on PBL were a significant susceptibility factor for nvCJD, young persons would display higher levels. Instead, the elderly expressed the highest amounts of PrP(C) on PBL. This argues against the hypothesis that variability in cell surface expression of PrP(C) in PBL contributes to the exquisite susceptibility of the young to nvCJD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10870113

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Transport of prion protein across the blood-brain barrier.

Authors:  W A Banks; Sandra M Robinson; R Diaz-Espinoza; A Urayama; C Soto
Journal:  Exp Neurol       Date:  2009-05-05       Impact factor: 5.330

Review 2.  The role of the cellular prion protein in the immune system.

Authors:  J D Isaacs; G S Jackson; D M Altmann
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

3.  Recent developments in the pathogenesis, diagnosis, and therapy of prion diseases.

Authors:  A Aguzzi
Journal:  Dialogues Clin Neurosci       Date:  2001-03       Impact factor: 5.986

4.  Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly.

Authors:  Agnieszka Jóźwik; Jerzy Landowski; Leszek Bidzan; Tamas Fülop; Ewa Bryl; Jacek M Witkowski
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

5.  Plasma soluble prion protein, a potential biomarker for sport-related concussions: a pilot study.

Authors:  Nam Pham; Hungbo Akonasu; Rhonda Shishkin; Changiz Taghibiglou
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

6.  Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS.

Authors:  Meredith A Mortberg; Hien T Zhao; Andrew G Reidenbach; Juliana E Gentile; Eric Kuhn; Jill O'Moore; Patrick M Dooley; Theresa R Connors; Curt Mazur; Shona W Allen; Bianca A Trombetta; Alison McManus; Matthew R Moore; Jiewu Liu; Deborah E Cabin; Holly B Kordasiewicz; Joel Mathews; Steven E Arnold; Sonia M Vallabh; Eric Vallabh Minikel
Journal:  JCI Insight       Date:  2022-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.